Core Viewpoint - *ST Suwu has been identified for financial fraud over four consecutive years, leading to potential mandatory delisting due to significant violations of regulations [1][2]. Financial Misconduct - The company has inflated its operating income and profits through non-commercial trade activities with related companies, resulting in a total inflated operating income of 1.772 billion yuan from 2020 to 2023, which accounted for 26.46%, 26.39%, 21.26%, and 16.82% of the reported operating income for each respective year [1]. - The inflated total profits during the same period amounted to approximately 75.9975 million yuan, representing 2.89%, 51.65%, 26.42%, and 29.81% of the reported total profits for each year [1]. Regulatory Actions - The China Securities Regulatory Commission (CSRC) has issued a warning to *ST Suwu, imposed a fine of 10 million yuan, and penalized the chairman, Qian Qunshan, with a total fine of 15 million yuan, including 5 million yuan for direct responsibility and 10 million yuan as the actual controller [4]. - Qian Qunshan is also subject to a 10-year ban from the securities market, prohibiting him from engaging in any securities-related activities during this period [4]. Company Background - Established in June 1994, *ST Suwu was previously known as a school-run enterprise and was listed on the Shanghai Stock Exchange in 1999, once referred to as "China's first stock in public education" [4]. - The company's main business involves drug research, production, and sales [4]. Financial Position - As of July 11, *ST Suwu's stock price was 2.42 yuan per share, with a market capitalization of 1.72 billion yuan [5]. - The company has reported significant non-operating fund occupation by related parties, with balances of 1.27 billion yuan, 1.393 billion yuan, 1.543 billion yuan, and 1.693 billion yuan from the end of 2020 to 2023, which represented 6.88%, 74.20%, 84.60%, and 96.09% of the disclosed net assets for those years [2].
四年虚增营收超17亿,“普教第一股”触及重大违法退市情形